Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04682509

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

Sponsor: NYU Langone Health

Conditions ESRD

Updated 7 times since 2021 Last updated: Jun 24, 2024 Started: Mar 20, 2022 Primary completion: May 16, 2023 Completion: Feb 28, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on ESRD, this trial is completed. The trial is conducted by NYU Langone Health and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1

Status: Active Not Recruiting → Completed
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting EARLY_PHASE1

Status: Enrolling By Invitation → Active Not Recruiting
May 2023 — Apr 2024 [monthly]

Enrolling By Invitation EARLY_PHASE1
Sep 2022 — May 2023 [monthly]

Enrolling By Invitation EARLY_PHASE1

Status: Not Yet Recruiting → Enrolling By Invitation

▶ Show 2 earlier versions

Dec 2021 — Sep 2022 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jan 2021 — Dec 2021 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NYU Langone Health

Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States